Metsera jumps as Novo challenges Pfizer in bidding war for obesity drug developer

Structure Therapeutics

30/10/2025 11:19

Updates

** Shares of obesity drug developer Metsera MTSR.O jump 16.8% to $60.99 premarket

** Novo Nordisk NOVOb.CO proposes $6.5 bln deal for Metsera, including debt, with an additional $2.5 billion in milestone-based payments via CVRs

** Last month, Pfizer PFE.N said it would acquire Metsera in a deal valued at up to $7.3 billion, including future payments

** Metsera develops early and mid-stage drugs for obesity and diabetes

** U.S.-listed shares of Novo Nordisk NOVOb.CO down 1% premarket

** Shares of MTSR's peer Structure Therapeutics GPCR.O  which also develops oral GLP-1 drugs for obesity rise 4.3% to $30.84 premarket

** "Novo's competitive bid continues to show that large Pharma has an interest in buying into obesity (even if they are already established with commercial assets) in order to capitalize on the significant market opportunity," brokerage BMO Capital Markets says

** Up to last close, MTSR up 97.01% since debut in January

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))